Nplate, ESAs In ESRD Setting On List For Potential National Coverage Action By CMS
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency seeks public comment on proposed list of drugs, devices and treatments that could get reimbursement scrutiny through the national coverage determination process.
You may also be interested in...
Avastin v. Lucentis: An Early Test Case For Medicare ACOs?
Medicare costs for covering Genentech’s Lucentis for wet age-related macular degeneration will get heightened scrutiny now that a widely anticipated National Institutes of Health trial has confirmed that much-less-expensive treatment with the company’s Avastin is as effective.
Avastin v. Lucentis: An Early Test Case For Medicare ACOs?
Medicare costs for covering Genentech’s Lucentis for wet age-related macular degeneration will get heightened scrutiny now that a widely anticipated National Institutes of Health trial has confirmed that much-less-expensive treatment with the company’s Avastin is as effective.
Medicare National Policy On ESAs In Renal Setting Opposed By Physicians, Patients And Amgen
They ask CMS, at the very least, to analyze claims data from the agency’s ESA monitoring policy before making any new coverage determinations.